Nabi Biopharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1967-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.nabi.com
CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2008-01-08
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 203
- Registration Number
- NCT00211939
- Locations
- 🇺🇸
University of Texas Health Sciences Center, San Antonio, Texas, United States
EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2008-01-08
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 110
- Registration Number
- NCT00211978
- Locations
- 🇺🇸
University of Texas Health Sciences Center, San Antonio, Texas, United States
StaphVAX Immunogenicity in Orthopedic Implant Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2008-01-04
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT00211926
- Locations
- 🇺🇸
Cllinical Research Asociates of Tidewater, Norfolk, Virginia, United States
Evaluation of Manufacturing Lot of StaphVAX
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2008-01-04
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 65
- Registration Number
- NCT00211900
- Locations
- 🇺🇸
Trialogic Research, Madison, Alabama, United States
Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2008-01-04
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 99
- Registration Number
- NCT00130260
- Locations
- 🇺🇸
multiple sites: contact Central Study coordination, Birmingham, Alabama, United States
Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis
Phase 3
Completed
- Conditions
- First Posted Date
- 2003-10-17
- Last Posted Date
- 2006-07-11
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 3600
- Registration Number
- NCT00071214
Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-08-11
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT00066989
Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-06-20
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00063089
© Copyright 2024. All Rights Reserved by MedPath